Dyslipidemia - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 174 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dyslipidemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H2 2014', provides an overview of the Dyslipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
Pipeline Products for Dyslipidemia - Overview 10
Pipeline Products for Dyslipidemia - Comparative Analysis 11
Dyslipidemia - Therapeutics under Development by Companies 12
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 16
Dyslipidemia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dyslipidemia - Products under Development by Companies 21
Dyslipidemia - Products under Investigation by Universities/Institutes 24
Dyslipidemia - Companies Involved in Therapeutics Development 25
Amgen Inc. 25
AstraZeneca PLC 26
GlaxoSmithKline plc 27
Daiichi Sankyo Company, Limited 28
Merck & Co., Inc. 29
Takeda Pharmaceutical Company Limited 30
Teijin Pharma Limited 31
Novartis AG 32
Biocon Limited 33
Chong Kun Dang Pharmaceutical Corp. 34
Dr. Reddy's Laboratories Limited 35
Kissei Pharmaceutical Co., Ltd. 36
Kowa Company, Ltd. 37
Zydus Cadila Healthcare Limited 38
Genfit SA 39
Nippon Chemiphar Co., Ltd. 40
Torrent Pharmaceuticals Limited 41
Debiopharm International S.A. 42
Jenrin Discovery, Inc. 43
Lipicard Technologies Limited 44
Cadila Pharmaceuticals Ltd. 45
Spherix Incorporated 46
Arisaph Pharmaceuticals, Inc. 47
Alder Biopharmaceuticals Inc. 48
Catabasis Pharmaceuticals, Inc. 49
Cerenis Therapeutics SA 50
Pharmena SA 51
Reviva Pharmaceuticals Inc. 52
Kotobuki Pharmaceutical Co., Ltd. 53
High Point Pharmaceuticals, LLC 54
Kadmon Corporation, LLC 55
Dezima Pharma B.V. 56
Dyslipidemia - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
anacetrapib - Drug Profile 70
K-877 - Drug Profile 72
evolocumab - Drug Profile 73
(rosuvastatin calcium + ezetimibe) - Drug Profile 75
Centatin - Drug Profile 76
DEZ-001 - Drug Profile 77
GFT-505 - Drug Profile 78
DRL-17822 - Drug Profile 81
K-877 - Drug Profile 82
TRIA-662 - Drug Profile 83
ZYH-7 - Drug Profile 85
(niacin + aspirin) - Drug Profile 86
KD-026 - Drug Profile 87
S-556971 - Drug Profile 88
MGL-3196 - Drug Profile 89
ARI-3037MO - Drug Profile 91
ZYT-1 - Drug Profile 92
HPP-593 - Drug Profile 93
NC-2400 - Drug Profile 94
TAP-311 - Drug Profile 95
S-556971 - Drug Profile 96
CKD-519 - Drug Profile 97
DS-1442 - Drug Profile 98
K-312 - Drug Profile 99
Debio-0930B - Drug Profile 100
SPX-8522876 - Drug Profile 101
VK-0214 - Drug Profile 102
(statin + niacin + aspirin) - Drug Profile 103
HDL Receptor Enhancer - Drug Profile 104
(SPX-106 + D-tagatose) - Drug Profile 105
CAT-2000 Series - Drug Profile 107
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 108
4655-K09 - Drug Profile 109
TEI-M01361 - Drug Profile 110
SPX-100 - Drug Profile 111
KTA-439 - Drug Profile 112
ND-630 - Drug Profile 113
First Generation Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia And Type 2 Diabetes - Drug Profile 114
Second Generation Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia And Type 2 Diabetes - Drug Profile 115
JD-5037 - Drug Profile 116
ZLN-005 - Drug Profile 117
TRC-210258 - Drug Profile 118
LT-5421 - Drug Profile 119
LT-5423 - Drug Profile 120
Peroxibrate - Drug Profile 121
Small Molecule for Cardiovascular and Metabolic Disorders - Drug Profile 122
BSN-852 - Drug Profile 123
CAT-2054 - Drug Profile 124
GSK-2041706 - Drug Profile 125
LP-071 - Drug Profile 126
ZLN-024 - Drug Profile 127
C-24 - Drug Profile 128
ND-654 - Drug Profile 129
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia - Drug Profile 130
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 131
ApoE4mut1 - Drug Profile 132
DF-461 - Drug Profile 133
DGAT-1 - Drug Profile 134
RP-17000 - Drug Profile 135
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 136
ALD-317 - Drug Profile 137
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 138
Dyslipidemia - Recent Pipeline Updates 139
Dyslipidemia - Dormant Projects 157
Dyslipidemia - Discontinued Products 160
Dyslipidemia - Product Development Milestones 161
Featured News & Press Releases 161
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 170
Disclaimer 170

List of Tables
Number of Products under Development for Dyslipidemia, H2 2014 14
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Development, H2 2014 23
Comparative Analysis by Unknown Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Dyslipidemia - Pipeline by Amgen Inc., H2 2014 29
Dyslipidemia - Pipeline by AstraZeneca PLC, H2 2014 30
Dyslipidemia - Pipeline by GlaxoSmithKline plc, H2 2014 31
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 32
Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2014 33
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 34
Dyslipidemia - Pipeline by Teijin Pharma Limited, H2 2014 35
Dyslipidemia - Pipeline by Novartis AG, H2 2014 36
Dyslipidemia - Pipeline by Biocon Limited, H2 2014 37
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 38
Dyslipidemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2014 39
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 40
Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2014 41
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 42
Dyslipidemia - Pipeline by Genfit SA, H2 2014 43
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2014 44
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 45
Dyslipidemia - Pipeline by Debiopharm International S.A., H2 2014 46
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2014 47
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2014 48
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H2 2014 49
Dyslipidemia - Pipeline by Spherix Incorporated, H2 2014 50
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 51
Dyslipidemia - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 52
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 53
Dyslipidemia - Pipeline by Cerenis Therapeutics SA, H2 2014 54
Dyslipidemia - Pipeline by Pharmena SA, H2 2014 55
Dyslipidemia - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 56
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2014 57
Dyslipidemia - Pipeline by High Point Pharmaceuticals, LLC, H2 2014 58
Dyslipidemia - Pipeline by Kadmon Corporation, LLC, H2 2014 59
Dyslipidemia - Pipeline by Dezima Pharma B.V., H2 2014 60
Assessment by Monotherapy Products, H2 2014 61
Assessment by Combination Products, H2 2014 62
Number of Products by Stage and Target, H2 2014 65
Number of Products by Stage and Mechanism of Action, H2 2014 68
Number of Products by Stage and Route of Administration, H2 2014 71
Number of Products by Stage and Molecule Type, H2 2014 73
Dyslipidemia Therapeutics - Recent Pipeline Updates, H2 2014 143
Dyslipidemia - Dormant Projects, H2 2014 161
Dyslipidemia - Dormant Projects (Contd..1), H2 2014 162
Dyslipidemia - Dormant Projects (Contd..2), H2 2014 163
Dyslipidemia - Discontinued Products, H2 2014 164